Clinical Trial Update: RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial RE002 T cell injection is assessing safety and preliminary efficacy in KRAS G12D-mutated solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• RE002 T Cell Injection

Snippet

Sponsor: Henan Cancer Hospital | Conditions: KRAS G12D, T Cell Therapy | Phase 1 | Status: RECRUITING